NEW DELHI (Reuters) - The cabinet on Tuesday approved Mylan Inc's
Mylan, one of the world's largest generic drugmakers, in February agreed to buy the Strides unit, Agila Specialities, for $1.6 billion to expand its presence in the fast-growing injectable drugs market.
(Reporting by Nigam Prusty)


